BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
BioPharm Executive - Golden Handshakes
Celgene (CELG) Slaps Down $450 Million Upfront for AstraZeneca PLC (AZN)'s Prized Immunotherapy Blood Cancer Drug 4/24/2015
Innate Pharma (IPH.PA ) Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC (AZN) 4/24/2015
BREAKING: Perrigo (PRGO) Rejects $30B Mylan (MYL) Bid, Says Deal "Substantially Undervalues" Irish Firm 4/21/2015
Tiny Curadev Wrangles a $555 Million Pact With Drug Giant Roche (RHHBY) 4/20/2015
uniQure (QURE) Soars After Bristol-Myers Squibb (BMY) Bets $1 Billion on Gene Therapy Platform 4/7/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
AstraZeneca PLC (AZN), Daiichi Sankyo in $825 Million Drug Tie-Up 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
AbbVie (ABBV) Overpaid in Pharmacyclics (PCYC) Deal, For Only 50% Rights to Imbruvica: Analyst 3/6/2015
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/5/2015
Spending Spree Continues as Valeant (VRX) Officially Snags Salix (SLXP) for $14.5 Billion 2/23/2015
Pfenex (PFNX), Hospira Pursue Lucentis Biosimilar in $342 Million Pact 2/11/2015
AstraZeneca PLC (AZN) Who? Pfizer (PFE) Snatches Up Hospira for $17 Billion Cash 2/6/2015
AstraZeneca PLC (AZN) Slams Down $600 Million for Actavis (ACT) Lung Unit 2/5/2015
Mylan (MYL), Theravance (THRX) Partner Up for $265 Million COPD Pact 2/2/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
Merck & Co. (MRK) Jumps Into RNA Frenzy With $100 Million Bet on Moderna Therapeutics, Inc. 1/14/2015
Tiny Vedanta Biosciences Forges $241 Million+ Pact With Johnson & Johnson (JNJ) 1/14/2015
Roche (RHHBY) Pays $1.03 Billion for Majority Stake in Foundation Medicine, Inc. (FMI) 1/12/2015
Shire (SHPGY) Officially Snaps Up NPS Pharmaceuticals, Inc. (NPSP) in $5.2 Billion Deal 1/12/2015
Opko Health, Inc. (OPK) Rockets After Striking Deal Worth $570 Million With Pfizer (PFE) 12/17/2014
Oncothyreon Inc. (ONTY) Strikes $300 Million Cancer Pact With Array BioPharma, Inc. (ARRY) 12/15/2014
Drug Giant Merck & Co. (MRK) Buys Cubist Pharmaceuticals, Inc. (CBST) For $9.5 Billion 12/11/2014
Spark Therapeutics Strikes $280 Million Hemophilia B Pact With Pfizer (PFE) 12/9/2014
GeNeuro, Servier Ink $455M MS Drug Pact 12/2/2014
Actavis (ACT) Agrees To Buy Allergan (AGN) For $66 Billion 11/18/2014
Pfizer (PFE), Merck KGaA (MKGAF.PK) Strike A $2.9B Deal To Develop Cancer Tumor Treatment 11/18/2014
Astellas Pharma Inc. (ALPMY), Proteostasis Therapeutics, Inc. Forge $1.2 Billion Genetic Disease Drug Pact 11/5/2014
Bristol-Myers Squibb (BMY) Strikes Deal Worth $444 Million With Galecto Biotech 11/4/2014
Five Prime Therapeutics, Inc. (FPRX) Snags An Expanded Deal Worth $196.3 Million With GlaxoSmithKline (GSK) 10/24/2014
SSF's Sutro Biopharma Forges $1 Billion+ And Option To Buy Pact With Celgene (CELG) 10/23/2014
Genentech (RHHBY), NewLink Genetics Strike $1 Billion+ Cancer Deal 10/21/2014
AbbVie (ABBV) Officially Abandons Shire 10/21/2014
Oxford BioMedica PLC (OXB.L) Inks Transformational $90 Million Deal With Novartis AG (NVS) 10/10/2014
South San Francisco's Sutro Biopharma Forges $375 Million Antibody Drug Pact With Merck KGaA (MKGAF.PK) 9/17/2014
Eli Lilly (LLY) Bets $500 Million On AstraZeneca PLC (AZN)’s Alzheimer's Drug 9/17/2014
More Than 35% Of Allergan Inc. (AGN) Investors Demand Special Meeting; Support For Valeant (VRX) Merger Grows 9/12/2014
Seattle Genetics, Inc. (SGEN), Genmab A/S (GEN.CO) Partner In $211 Million Antibody-Drug Pact 9/10/2014
AbbVie (ABBV) Hands Over $275 Million Upfront For Infinity Pharmaceuticals Inc. (INFI)’s Blood Cancer Drug; Deal Could Be Worth $805 Million 9/5/2014
Roche (RHHBY) Pays $8.3 Billion For Bay Area's InterMune (ITMN), Pledges To Keep Employees 8/26/2014
Pfizer (PFE) Eyes Possible Actavis (ACT) Bid Whilst Weighing Next Steps Over AstraZeneca PLC (AZN) 8/22/2014
Sanofi (France) (SAN.PA) To Pay MannKind Corporation (MNKD) Up To $925 Million For Inhaled Insulin 8/12/2014
Novartis AG (NVS), GlaxoSmithKline (GSK) Reshape Pharma With Game-Changing $14.5 Billion Deal 8/12/2014
Sanofi (France) (SAN.PA), Immune Design Corporation (IMDZ) Strike Food Allergy Deal Worth $168 Million+ 8/7/2014
Mylan Inc. (MYL)'s Overseas Move Will Lower Tax Rate 7/23/2014
AbbVie (ABBV) Finally Clinches Shire For $54 Billion 7/21/2014
Novartis AG (NVS), Google Inc. Strike Smart Contact Lenses Pact 7/15/2014
Genentech (RHHBY) To Pay Up To $1.7 Billion For San Diego Biotech Firm Seragon Pharmaceuticals 7/7/2014
Massachusett's bluebird bio (BLUE) Snaps Up Pregenen For Up To $139.9 Million 7/2/2014
Tapping University of California, San Francisco (UCSF) Invention, Roche (RHHBY) To Partner With San Diego Startup Inception Sciences, Versant Ventures To Form New Multiple Sclerosis Company 6/24/2014
Major Drugmakers Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK). And Johnson & Johnson (JNJ) Link Up With Academia In Huge $27 Million UK Dementia Project 6/20/2014
AstraZeneca PLC (AZN) Beefs Up Pipeline With $232 Million Synairgen plc Asthma Deal 6/12/2014
Merck & Co., Inc. (MRK) Snags Cambridge's Idenix Pharmaceuticals, Inc. (IDIX) For $3.85 Billion 6/11/2014
Adaptimmune Ltd., GlaxoSmithKline (GSK) Strike $350 Million Cancer Immunotherapy Pact 6/2/2014
Neurotez, Inc., GCA Therapeutics Strike $102.5 Million+ Alzheimer's Pact 5/21/2014
AstraZeneca PLC (AZN) Rejects Pfizer Inc. (PFE)'s Final Offer 5/20/2014
Ophthotech Corporation (OPHT) May Pocket $1 Billion From Eye Drug Deal With Novartis AG (NVS), Ophthotech Stock Up +24.48% At Market Close (May 20, 2014) 5/20/2014
Valeant Pharmaceuticals International (VRX) Will Sweeten $46 Billion Allergan Inc. (AGN) Bid 5/14/2014
Lundbeck Inc. (LUN.CO) Swallows Up Chelsea Therapeutics, Inc. (CHTP) In Deal Worth $658 Million 5/9/2014
Pfizer Inc. (PFE) Still Wants AstraZeneca PLC (AZN) After $98.7 Billion Bid Rejected 4/29/2014
Celgene Corporation (CELG) Antes Up $710 Million Upfront For Phase 3-Ready Crohn's Disease Drug 4/24/2014
Allergan Inc. (AGN) Curls Up Into Poison-Pill Position In Wake Of Valeant Pharmaceuticals International (VRX), Ackman Acquisition Bid 4/23/2014
FORMA Therapeutics, Inc. Picks Up Another $225 Million, And A Potential Buyout From Celgene (CELG) 4/2/2014
Baxter International, Inc. (BAX) To Split Into Two Companies, Spins Off $6 Billion Biotech Biz 3/28/2014
MedImmune (AZN), MD Anderson Cancer Center Agree To Launch Moon Shot At Cancer 3/20/2014
Five Prime Therapeutics, Inc. (FPRX), Bristol-Myers Squibb Company (BMY) Strike $350 Million Immuno-Oncology Pact 3/18/2014
Charles River Laboratories (Massachusetts) Shells Out $179 Million Cash To Buy Galapagos NV (GLPG.BR)'s CRO Services Division 3/13/2014
Top Biopharmas Such As Abbott Laboratories (ABT) And GlaxoSmithKline (GSK) Still Betting On "Messed Up" Indian Drugs Market 3/12/2014
Novartis AG (NVS) Chairman Rules Out Merger With Roche (RHHBY) 3/3/2014
Actavis (ACT) Bags Rival, Forest Laboratories, Inc. (FRX), For $25 Billion; Forest Stock Rockets +27.52% At Market Close (February 18, 2014) 2/19/2014
CoStim Pharmaceutical Buyout Bolsters Novartis AG (NVS)'s Cancer Portfolio 2/18/2014
Mallinckrodt Pharmaceuticals (MNK) Adds Pain Drug With $1.3 Billion Cash Cadence Pharmaceuticals, Inc. Buyout 2/11/2014
Eli Lilly and Company (LLY), Pfizer Inc. (PFE) And Eight Other Rivals Join The National Institutes of Health (NIH) In $230 Million Deal To Search For New Drugs 2/5/2014
Ablynx (ABLYF), Merck & Co., Inc. (MRK) Forge Cancer Pact Worth $2.3 Billion 2/3/2014
Nantbioscience Scores $75 Million Cancer Deal With Celgene Corporation (CELG) 1/16/2014
Regeneron (REGN), Bayer HealthCare (BAY) Forge Pact Worth $65 Million+ To Co-develop Wet AMD Drug 1/14/2014
Jazz Pharmaceuticals plc (JAZZ) Forges Pact Worth $397 Million For Aerial BioPharma's Sleepiness Drug 1/13/2014
Santaris Pharma A/S, Roche (RHHBY) Strike $148 Million+ Alliance To Design And Develop RNA-Targeted Drugs 1/10/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) May Pay Sangamo BioSciences, Inc. (SGMO) As Much As $320 Million For Blood Drugs; SGMA Soars +38.32% At Market Close (January 9, 2014) 1/9/2014
Roche (RHHBY) Inks Deal Worth Up To $600 Million For Prothena Corporation plc's Parkinson's Drug 12/13/2013
Biogen Idec, Inc. (Massachusetts) (BIIB), Proteostasis Therapeutics, Inc. Hammer Out $200 Million+ Pre-Clinical Alzheimer's Pact 12/9/2013
AstraZeneca PLC (AZN) Said To Be Eyeing Forest Laboratories, Inc. (FRX) Takeover Bid 12/4/2013
Roche (RHHBY), Molecular Partners AG Ink $1 Billion+ Cancer Pact 12/4/2013
Celgene Corporation (CELG) Smacks Down $177 Million Upfront For OncoMed Pharmaceuticals, Inc. (OMED)'s Stem Cell Drugs, Deal Is Potentially Worth $3.3 Billion; OMED Stock Up 97.86% at Market Close (December 3, 2013) 12/4/2013
immatics biotechnologies GmbH, Roche (RHHBY) Ink Cancer Pact Worth Up To $1 Billion 11/13/2013
Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated (VPHM) 11/11/2013
ImmunoGen, Inc. (IMGN) Is On A Roll, Inks Fifth New License Agreement Of 2013 11/11/2013
Salix Pharmaceuticals, Ltd. (SLXP) Bags Santarus Inc. (SNTS) for $2.6 Billion to Beef Up Gastro Drug Line-Up 11/8/2013
Roche (RHHBY) to Pay Polyphor Up to $548 Million for Superbug Antibiotic 11/4/2013
Startup NextCODE Health, Launches Operations With $15 Million in Venture Financing 10/23/2013
Amgen (AMGN) Acquires Filgrastim Franchise Rights From Roche (RHHBY) in 100 Markets 10/23/2013
PDL BioPharma, Inc. (PDLI) Snatches Up Depomed, Inc. (DEPO)'s Diabetes Portfolio for $240.5 Million 10/22/2013
AmpliPhi Biosciences (TGEN) Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies 10/17/2013
AstraZeneca PLC (AZN)'s MedImmune (AZN) Takes Over Spirogen Ltd. for Up to $400 Million to Bolster Oncolology Portfolio 10/15/2013
Ablynx (ABLYF) Scores $840 Million Inflammatory Drug Pact With AbbVie (ABBV); Ablynx Stock Rises 24.73% at Market Close (September 23, 2013) 9/23/2013
Clovis Oncology (CLVS) Looking to Sell Itself 9/18/2013
Roche (RHHBY), Inovio Pharmaceuticals (INO) Strike Vaccines Pact Worth $422.5 Million 9/11/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Makes $100 Million Upfront Payment in R&D Neurological Disorders Pact With Isis Pharmaceuticals, Inc. (ISIS) 9/9/2013
Japan's Otsuka Pharmaceutical Co., Ltd. Shells Out $886 Million for U.S. Cancer Firm Astex Pharmaceuticals (ASTX) 9/5/2013
Amgen (AMGN) Finally Reaches Deal to Buy Onyx Pharmaceuticals, Inc. (ONXX) for $10.4 Billion, AMGN Stock Rockets +7.72% on Monday @ Market Close (August 26, 2013) 8/26/2013
Adimab LLC. Adds Celgene Corporation (CELG) to Its Growing List of Big-Name Drugmaking Partners 8/20/2013
Shire plc Hires Adviser on Takeover Threat 8/20/2013
Array BioPharma, Inc. (ARRY) Says Amgen (AMGN) Ends Agreement, to Cut 20 Percent of Jobs 8/9/2013
Jazz Pharmaceuticals plc (JAZZ) and Alkermes plc (ALKS) are Seen as Next Targets Amid Irish Deal Frenzy: Real M&A 8/6/2013
Transition Therapeutics Inc. (TTH.TO) Buys Rights to Eli Lilly and Company (LLY)'s Arthritis Drug; Transition May be Eligible for $130 Million+ 7/24/2013
Pfizer Inc. (PFE) Not Moving Forward With Onyx Pharmaceuticals, Inc. (ONXX) Bid: Sources 7/19/2013
Quest Diagnostics Inc. (DGX) Sells Ibrutinib Royalty Rights to Royalty Pharma for $485 Million in Cash 7/18/2013
Spectrum Pharmaceuticals, Inc. (SPPI) Snaps Up Talon Therapeutics, Inc. (TLON.OB) in $206.3 Million Deal 7/17/2013
Array BioPharma, Inc. (ARRY), Loxo Oncology Strike $434 Million+ Cancer Pact 7/11/2013
AstraZeneca PLC (AZN) and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership 6/17/2013
Johnson & Johnson (JNJ) to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion 6/17/2013
Johnson & Johnson (JNJ) Sells Final Stake in Elan Corporation PLC (ELN) for $332 Million 6/14/2013
Cytokinetics, Inc. (CYTK), Amgen (AMGN) Expand $75 Million Development Deal Into Japan 6/12/2013
AstraZeneca PLC (AZN) in Deal for Pearl Therapeutics Worth Up to $1.15 Billion 6/11/2013
Actavis (ACT) Nabs Warner Chilcott, PLC (WCRX) for $8.5 Billion 5/20/2013
AbbVie (ABBV), Galapagos NV (GLPG.BR) Ink $50 Million Crohn's Disease Pact 5/17/2013
AstraZeneca PLC (AZN), Cubist Pharmaceuticals, Inc. (CBST), Astellas Pharma Inc. (YPH.BE) Said to Make Bids for Optimer Pharmaceuticals, Inc. (OPTR) 5/15/2013
Elan Corporation PLC (ELN) Bets $1 Billion on Theravance, Inc. (THRX) Drugs; Move to Spurn Its Hostile Suitor? 5/13/2013
Concert Pharmaceuticals, Inc. and Celgene Corporation (CELG) Tie the Knot in a $300 Million Tech Deal 5/6/2013
Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China 4/15/2013
GlaxoSmithKline (GSK) Targets "Electroceuticals" for Potential New Therapies 4/11/2013
GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical Engineering and Sciences to Develop New Medicines for Emerging Markets 4/9/2013
Resverlogix Corporation (RVX.TO) to Spin-Out RVX Therapeutics Inc. (RVX) 4/8/2013
Roche (RHHBY) and Isis Pharmaceuticals, Inc. (ISIS) Form $392 Million Alliance for Huntington's Disease 4/8/2013
AstraZeneca PLC (AZN) Shells Out $240 Million Upfront for Moderna Therapeutics mRNA Drugs 3/22/2013
bluebird bio Forms Cancer Drug Partnership With Celgene Corporation (CELG) 3/21/2013
Receptos Licenses AbbVie (ABBV) Antibody for Co-Development 3/14/2013
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors 3/13/2013
Presage Biosciences Snags $13 Million From Celgene Corporation (CELG) to Pick Winning Cancer Drug Combos 3/5/2013
Roche (RHHBY) and Chiasma Inc. to Ally on Drug Development for Up to $600 Million 2/20/2013
Merck & Co., Inc. (MRK) and Samsung Corporation to Develop Biosimilar Drugs Together 2/20/2013
RQx Pharmaceuticals, Inc. Inks $111 Million Genentech (RHHBY) Deal 2/12/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) to Buy Elan Corporation PLC (ELN)'s Tysabri Rights for $3.25 Billion 2/7/2013
The Medicines Company (MDCO) Buys Cholesterol Drug Rights From Alnylam Pharmaceuticals (ALNY) for Up to $205 Million 2/5/2013
Allergan Inc. (AGN) to Buy MAP Pharmaceuticals, Inc. (MAPP) for $958 Million 1/23/2013
Life Technologies (LIFE) Gains on Buyout Speculation 1/21/2013
Shire plc Rises on AstraZeneca PLC (AZN) Bid Talk: Traders 1/17/2013
Amgen (AMGN), BIND Biosciences, Inc. Ink $180 Million Tumor Treatment Deal 1/8/2013
MacroGenics, Inc.'s DART Platform Grabs Potential $1 Billion Gilead Sciences, Inc. (GILD) Deal 1/8/2013
Gilead Sciences, Inc. (GILD) Bags Blood Disorder Drug With $510 Million YM BioSciences (YM.TO) Buy 12/13/2012
Amgen (AMGN) Bags Gene-Hunting Firm deCODE genetics, Inc. (DCGN) for $415 Million Cash 12/11/2012
Teva Pharmaceutical Industries Limited (TEVA) Enters $376 Million Deal for Xenon Pharmaceuticals Inc. Pain Drug 12/11/2012
Biogen Idec, Inc. (Massachusetts) (BIIB), Isis Pharmaceuticals, Inc. (ISIS) in Drug Development Pact for Up to $630 Million 12/10/2012
Sanofi (France) (SAN.PA) Deal Could Net Selecta Biosciences, Inc. $900 Million 11/29/2012
Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK) Team Up to Form Clinical Trial Site Database 11/15/2012
Forest Laboratories, Inc. (FRX) and Adamas Pharmaceuticals Form Alliance for Up to $160 Million 11/14/2012
Foundation Medicine and AstraZeneca PLC (AZN) Announce Genomic Profiling Collaboration 11/12/2012
Takeda Pharmaceutical Co. Ltd. (TKPYY) Shells Out $140 Million for Envoy Therapeutics 11/6/2012
Amgen (AMGN) Closes Deal With Financial Firm to Open New Biotech Company Atara Biotherapeutics 10/29/2012
Pfizer Inc. (PFE) Will Buy NextWave Pharmaceuticals for Up to $680 Million 10/23/2012
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/16/2012
Theravance, Inc. (THRX), Merck & Co., Inc. (MRK) Ink $153 Million Cardiovascular Pact 10/16/2012
AstraZeneca PLC (AZN) Boosts Pipeline With $272 Million Ardelyx Inc. Drug Deal 10/9/2012
Evotec AG (EVTG.F) and Bayer AG (BAY.F) Enter Into $765 Million Multi-Target Alliance to Fight Endometriosis 10/1/2012
MacroGenics, Inc. Could Earn More Than $1 Billion Through New Servier Alliance 9/20/2012
Baxter International, Inc. (BAX) and Onconova Therapeutics Inc. Announce European Licensing Agreement for Up to $515 Million 9/19/2012
Complete Genomics, Inc. to be Bought by Chinese Firm for $117.6 Million 9/17/2012
AstraZeneca PLC (AZN)'s MedImmune (AZN) Forms Chinese Joint Venture for Biologic Drug 9/11/2012
Genmab A/S (GEN.CO) Inks $1.1 Billion Deal With Johnson & Johnson (JNJ) 8/31/2012
Allergan Inc. (AGN), Molecular Partners AG Ink $1.5 Billion Exclusive Pact 8/21/2012
AstraZeneca PLC (AZN) Buys Into Regulus Therapeutics, Inc.' MicroRNA Therapeutics for $28 Million 8/15/2012
Elan Corporation PLC (ELN) Fuels Buyout Plans With $130 Million R&D Spinout, Unit Will Have Around 80 Staffers 8/14/2012
S*Bio of Singapore Sells Cancer Drug Rights to MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) for $75 Million 8/10/2012
GlaxoSmithKline (GSK) Completes $3.6 Billion Takeover of Human Genome Sciences, Inc. (HGSI) 8/6/2012
Life Technologies (LIFE) Buys Navigenics for Genetic Diagnostics 7/17/2012
GlaxoSmithKline (GSK) Clinches Deal to Buy Human Genome Sciences, Inc. (HGSI) for $2.8 Billion 7/16/2012
Verastem, Inc. (VSTM) Buys Pfizer Inc. (PFE) Cancer Drug Candidate in Deal Worth $126.5 Million 7/12/2012
Alnylam Pharmaceuticals (ALNY), Ascletis, Inc. Create Strategic Collaboration to Develop ALN-VSP 7/12/2012
AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Join Forces in $7 Billion Deal for Amylin Pharmaceuticals, Inc. (AMLN) 7/3/2012
Roche (RHHBY)'s Genentech (RHHBY) Grabs Alzheimer's Drug Rights From AC Immune SA for $418 Million-Plus 6/19/2012
AstraZeneca PLC (AZN), Rigel Pharmaceuticals, Inc. (RIGL) Strike Potential $100 Million Asthma Drug Deal 6/19/2012
GlaxoSmithKline (GSK) Rumored to be Buying $5 Billion BioMarin Pharmaceutical Inc. (BMRN) 6/13/2012
GlaxoSmithKline (GSK) Pays $227 Million for Basilea Pharmaceutica (BSLN.SW) Eczema Drug 6/12/2012
AstraZeneca PLC (AZN) Bids $4 Billion for Diabetes Specialist Amylin Pharmaceuticals, Inc. (AMLN) 6/5/2012
Basilea Pharmaceutica (BSLN.SW) Participates in Public-private Collaboration to Tackle Antibiotic Resistance 5/25/2012
Agilent Technologies Inc. (A) to Acquire Dako North America, Inc. for $2.2 Billion 5/17/2012
GlaxoSmithKline (GSK)'s $2.6 Billion Bid for Human Genome Sciences, Inc. (HGSI) Goes Hostile 5/10/2012
Novartis AG (NVS) Snags Fougera (AAA) for $1.5 Billion for Generic Skin Drugs 5/3/2012
Axerion Therapeutics Inc., AstraZeneca PLC (AZN) Inks Pact to Combat Alzheimer's Disease 5/2/2012
Amylin Pharmaceuticals, Inc. (AMLN) Explores Sale, Hires Bankers: Sources; Is AstraZeneca PLC (AZN) Interested? 4/24/2012
AstraZeneca PLC (AZN) to Acquire Ardea Biosciences, Inc. for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout 4/23/2012
Human Genome Sciences, Inc. (HGSI) Rejects GlaxoSmithKline (GSK)'s $2.6 Billion Bid, Seeks Higher Offers 4/20/2012
Roche (RHHBY) Ready to Walk Away From $6.8 Billion Illumina, Inc. (ILMN) Bid 4/19/2012
Amgen (AMGN) to Pay $315 Million for Privately-Held KAI Pharmaceuticals, Inc. 4/11/2012
Watson Pharmaceuticals, Inc. (WPI) Close to $7 Billion Actavis Drug Deal: Sources 3/22/2012
Heptares Grants Shire plc an Exclusive Worldwide $190 Million License to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3/20/2012
BioCon Limited (BIOCON.NS) Plunges After Pfizer Inc. (PFE) Scraps $350 Million Insulin Pact 3/14/2012
EpiStem Ltd Announces a Three Year Collaboration With GlaxoSmithKline (GSK) in Fibrosis Research 3/13/2012
Mersana Therapeutics, Inc. Strikes $270 Million Antibody-drug Conjugate Deal With Endo Pharmaceuticals (ENDP) 3/7/2012
AngioChem, GlaxoSmithKline (GSK) Form $331 Million Pact to Discover and Develop Treatments of Lysosomal Storage Diseases 2/27/2012
Enanta Pharmaceuticals, Inc. Strikes Hep C Drug Deal With Novartis AG (NVS) Worth Up to $440 Million 2/22/2012
Pfizer Inc. (PFE) Eyes Tie-Ups With More Chinese Drugmakers; Will Ally With Zhejiang Hisun to Invest $545 Million in Generic Drug JV 2/21/2012
Roche (RHHBY) Digs in for Long Fight as Illumina, Inc. (ILMN) Rejects $5.7 Billion Bid 2/10/2012
Merck KGaA (MKGAF.PK) Signs $550 Million Cancer Pact With Threshold Pharmaceuticals, Inc. (THLD) 2/3/2012
Genentech (RHHBY) Pours $95 Million into Constellation Pharmaceuticals Epigenetic Drug Platform, Deal Includes M&A Terms 1/17/2012
Roche (RHHBY) Signs $646 Million Pain Pact With Xenon Pharmaceuticals Inc. 1/10/2012
Bristol-Myers Squibb Company (BMY) to Acquire Inhibitex, Inc. (INHX) for $2.5 Billion 1/9/2012
FORMA Therapeutics, Inc. Cuts $815 Million Deal With Boehringer Ingelheim Corporation to Discover Cancer Drugs 1/5/2012
Alexion Pharmaceuticals Inc. (ALXN) to Pay $1 Billion for Enobia Pharma 12/29/2011
Pharmacyclics, Inc. (PCYC) Could Get $975 Million in Johnson & Johnson (JNJ) License Deal 12/9/2011